Cooperative Agreement U01FD008657
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $250K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Pittsburgh, PA 15222, USA
Similar Awards
- The Cooperative Agreement award U01FD008415, provided by the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103), is supporting research to evaluate the suitability of Emulate Inc.'s Liver-Chip technology for predicting drug-induced liver injury (DILI) risk. The $250,000 award, running from September 2024 to August 2026, aims to demonstrate the reproducibility and performance of the Liver-Chip across multiple human hepatocyte donors. This research supports critical...
- This Cooperative Agreement award from the U.S. Food and Drug Administration (FDA), under the FDA Research program (CFDA 93.103), provides $245,356 to Perspectum, Inc. to conduct a retrospective, multi-center longitudinal observational study. The study aims to collect and analyze magnetic resonance cholangiopancreatography (MRCP) data to generate 3D models and associated MRCP+ metrics, specifically focused on the MRCP+ metric "number of strictures." The goal is to determine how...
- This Cooperative Agreement awarded by the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $249,580.00 to support the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center in conducting a series of studies to establish the analytic validity of non-calcified plaque volume (NCPV) measured by coronary CT angiography (CCTA) as a prognostic biomarker for coronary artery disease. The key objectives are to standardize the precision,...
- This Project Grant award of $1,982,628.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research to develop advanced methods for detecting liver fibrosis and creating a predictive diagnostic model for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in primary care settings. The project aims to improve identification of...
- This Cooperative Agreement award from the Food and Drug Administration (FDA) under the Food and Drug Administration Research program (CFDA 93.103) provides $150,000 in funding to the Pharmaceutical Inspection Co-Operation Scheme-Association De Droit Suisse to develop curricula and training tools for a web-based educational center called the PIC/S Inspectorates' Academy (PIA). The goal is to harmonize and standardize Good Manufacturing Practice (GMP) training and qualification processes for...
- This Cooperative Agreement award from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $1,496,492.00 to the Sloan-Kettering Institute for Cancer Research to conduct research on elucidating tumor-specific cell surface proteomes in ultra-rare cancers like rhabdoid tumors and desmoplastic small round cell tumors. The goal is to gain a better understanding of these challenging, therapy-resistant cancers and identify potential new therapeutic targets. The...
- This $1,999,999 Cooperative Agreement awarded by the Center for Drug Evaluation and Research (CDER), part of the U.S. Food and Drug Administration (CFDA 93.103 Food and Drug Administration Research), will support the development, dissemination, and evaluation of an evidence-based clinical practice guideline for managing perioperative pain associated with abdominal laparoscopic surgeries. The project, titled "Managing Perioperative Pain with Abdominal Laparoscopic Surgery: A Collaborative to...
- This Cooperative Agreement award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) is for $250,000.00 to support the Critical Path Institute (C-Path) in conducting psychometric analyses and generating a quantitative study report to qualify the Pediatric Asthma Diary-Child (PAD-C) and Pediatric Asthma Diary-Observer (PAD-O) measures. These clinical outcome assessment tools are intended to evaluate the severity of asthma symptoms and signs in children under 12 years old to...
- This Cooperative Agreement award from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $499,994 to Mainehealth to study and test solutions for increasing the enrollment of non-English speaking research subjects in clinical trials. The project, titled "Increasing Clinical Trial Opportunities and Enrollment of Non-English Speaking Research Subjects: A Revised Research Pathway (INCLUDE)", aims to develop a culturally appropriate and efficient...
- This Project Grant award of $303,257 from the Department of Health and Human Services National Institutes of Health (CFDA 93.310 Trans-NIH Research Support) to the Regents of the University of Michigan aims to improve a computational drug repositioning framework called ASGARD to repurpose existing drugs for primary liver cancers. The project will leverage single-cell RNA sequencing data to better account for the complexity of the tumor ecosystem, including genetic information and interactions...